-
Symbol
-
LYEL on Nasdaq
-
Investment type
-
Equity / Common Stock, par value $0.0001 per share
-
Latest Disclosed Ownership
-
27.2M shares
-
Security Ownership
-
9.2%
James B. Tananbaum ownership in Lyell Immunopharma, Inc. Common Stock, par value $0.0001 per share (LYEL)
2025-05-15 - James B. Tananbaum has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 27.2M shares of Lyell Immunopharma, Inc. Common Stock, par value $0.0001 per share (LYEL).
This represents 9.2% percent ownership of the company.
In their previous filing dated 2025-02-14, Foresite Capital Fund IV, L.P. had reported owning 19.5M shares, indicating an increase of 39.4% percent.